Several studies have shown that, in patients undergoing transrectal prostate biopsy, administration of prophylactic antibiotics results in a lower incidence of post-biopsy febrile episodes, [3] [4] [5] positive urine cultures and bacteraemia. [3] [4] [5] [6] [7] [8] However, little consensus exists as to the most appropriate antibiotic regimen. In a recent survey of 106 radiology and urology departments, we found a total of 48 different regimens utilizing 13 antibiotics. Metronidazole (administered po or pr) was the most commonly used antibiotic, featuring in 55% of regimens, followed by oral ciprofloxacin in 48% of regimens. Gentamicin (iv) was used in 48% of regimens and oral trimethoprim in 14%. Most regimens (89.7%) utilized an oral antibiotic. Of the regimens, 58.6% included an intravenous antibiotic and 29.3% combined intravenous, oral and rectally administered antibiotics; 29.3% of regimens consisted of oral antibiotics alone.
Few prospective studies have addressed the issues of antibiotic type, dose, route of administration, duration of treatment and cost in prophylaxis of transrectal prostatic biopsy.
The efficacy of oral ciprofloxacin compared with intravenous gentamicin as prophylaxis against bacteraemia after transrectal prostate biopsy has been demonstrated. 9 Patients received either 500 mg ciprofloxacin 12 h before biopsy and 12 h later or 1.5 mg/kg gentamicin intravenously 2 h before biopsy and 80 mg 8 h later. Of the patients who received gentamicin, 37% had bacteraemia after biopsy compared with 7% of those in the ciprofloxacin group. None of the patients given ciprofloxacin developed clinical signs of bacteraemia whereas six of those in the gentamicin group did. The authors concluded that the advantage of ciprofloxacin as prophylaxis against bacteraemia might be due to the drug's known ability to concentrate in the prostate gland. The authors recommended ciprofloxacin as prophylaxis because, compared with gentamicin, it is less nephrotoxic and ototoxic, less expensive and can be administered orally. 9 In a recent review of the fluoroquinolones 10 the question of their efficacy as prophylaxis in transrectal prostate biopsy was not addressed specifically but the author did recommend that a quinolone be used as first-line therapy in patients with complicated Gram-negative urinary tract infections. In this setting, norfloxacin is cheaper than ciprofloxacin and may be as effective. 10 The fluoroquinolones are active against Escherichia coli which has frequently been isolated from the blood and urine of patients after transrectal prostate biopsy. 3, 6, 7, 9, 11, 12 However, they are not reliably active against anaerobes. Bacteroides fragilis was the most common anaerobe isolated from blood cultures of patients after transrectal prostate biopsy and two deaths from anaerobic sepsis have been reported. 13, 14 Conflicting results were found in a recent study comparing a single dose of oral metronidazole 500 mg and intravenous netilmicin 1.5 mg/kg administered 1 h before biopsy with oral co-trimoxazole 1920 mg. 11 The rates of bacteraemia were comparable (37% in the former group and 28% in the latter) but the rate of urinary tract infection was 17% in the netilmicin-metronidazole group and only 2% in the co-trimoxazole group. Co-trimoxazole was preferred as prophylaxis because of its efficacy in preventing urinary tract infection, convenient route of administration and lower cost relative to aminoglycosidecontaining regimens.
11 However, the relatively high incidence of bacteraemia noted in this study in the cotrimoxazole group suggests that it may be inappropriate in patients predisposed to endocarditis who are undergoing transrectal prostate biopsy.
The clinical and microbiological outcome of a single intravenous dose of cefuroxime 1.5 g or a combination of piperacillin and tazobactam 4.5 g given 20 min before biopsy has been compared. 12 No significant difference was found between the two groups in the incidence of pyrexia 37.5°C or symptoms of urinary or systemic sepsis after biopsy. However, one patient who had received cefuroxime developed E. coli septicaemia requiring hospital admission and treatment with broad-spectrum antibiotics. Sixteen patients in the piperacillin-tazobactam group complained of diarrhoea and eight had nausea. 12 It is important to recognize that cefuroxime and piperacillintazobactam are expensive, costing £5.29 and £13.16 respectively, 15 a matter for consideration in budgetconscious departments.
The issue of duration of antibiotic cover in transrectal prostate biopsy has yet to be resolved. However, a recent study showed that no episodes of fever 38.5°C were found in patients who received norfloxacin starting 48 h before biopsy and continued for 4 days, compared with a 9% incidence of fever in those who received norfloxacin 30 min to 1 h before biopsy and then for 48 h, suggesting that a longer pre-operative course of antibiotics is protective against sepsis. 16 Other workers have found an overall infection rate of 6% after transrectal prostate biopsy in patients who received pre-and post-biopsy antibiotics compared with 39% in patients who received post-biopsy antibiotics alone. 4 It is thus recommended that antimicrobial agents should be started some time before transrectal prostate biopsy. 4 Our recent survey showed a wide variation in cost (ranging from £38.70/100 patients to £2136/100 patients) of the various antibiotic regimens used as prophylaxis for transrectal prostate biopsy. This has important fiscal implications as antibiotics are estimated to account for 50% of hospital drug budgets, largely as a result of the use of expensive parenteral agents. 17 Needles, syringes and intravenous access equipment further increase this cost. Gaining intravenous access and preparing, mixing and administering parenteral antibiotics is time consuming and adds further to the costs. Oral antibiotics are therefore a better choice, providing they are of comparable efficacy.
There is a clear lack of standardization in antibiotic prophylaxis for transrectal prostate biopsy with widely varying costs for the different regimens. A review of the literature confirms that oral antibiotic prophylaxis is effective in preventing infective complications associated with the procedure. Oral trimethoprim is inexpensive and in combination with sulphamethoxazole has been shown to reduce significantly the incidence of urinary tract infection in patients undergoing transrectal prostate biopsy. However, it is less efficacious than parenteral drugs in reducing the incidence of bacteraemia in such patients. Oral ciprofloxacin is inexpensive, well tolerated and effective at reducing the incidence of bacteraemia and clinical sepsis following transrectal prostate biopsy. On the other hand, it has poor activity against anaerobes and comparative prospective studies of ciprofloxacin, or the cheaper fluoroquinolone norfloxacin, alone and in combination with metronidazole are needed. Whenever it is used, oral metronidazole is cheaper and easier to administer than metronidazole suppositories.
